Humacyte Inc is a biotechnology company focused on developing and commercializing innovative regenerative medicine products, specifically human acellular vessels (HAVs) designed for use in vascular surgeries
The company utilizes its proprietary tissue engineering platform to create off-the-shelf, biocompatible vessels that can address the limitations of traditional grafts in treating various vascular conditions. Humacyte aims to improve patient outcomes by providing solutions that enhance the healing process, reduce the risk of complications, and ultimately expand access to life-saving surgical treatments.
FDA extends review timeline for Humacyte's FDA marketing application for its acellular tissue-engineered vessel in vascular trauma. Originally set for August 2024, the new action date remains undisclosed.
Humacyte has so far added Dr. John P. Bamforth and Dr. Keith Anthony to its Board of Directors, entered a license agreement with Pluristyx and received Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA for its Acellular Tissue Engineered Vessel.
